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Abstract
Diabetic nephropathy (DN) is the leading cause of end stage renal disease (ESRD), and is associated
with high morbidity and mortality rates. Key histological changes observed in DN include
accumulation of extracellular matrix (ECM) proteins and tubulointerstitial fibrosis. Meprins are
metalloproteinases that are abundantly expressed in the brush border membranes of proximal kidney
tubules. Meprins are also expressed in leukocytes (monocytes and macrophages) and podocytes.
Meprins cleave/degrade extracellular matrix (ECM) proteins such as collagen IV, collagen VI,
fibronectin, laminin, and nidogen-1 in vitro. Meprins have been implicated in the pathology of DN.

Sepsis is a complex medical condition, where the entire body undergoes an inflammatory state
and the presence of a known or suspected infection leads to severe consequences such as
multiple organ failure. Acute renal failure (ARF) is a common complication of sepsis. The
objective of this study was to evaluate cecal ligation and puncture (CLP)-induced sepsis in meprin
deficient mice with type 1 diabetes as a co-morbidity. Low dose Streptozotocin (STZ) was used to
induce type-1 diabetes in wild-type (WT) C57BL/6 mice which express high levels of both meprin A
and meprin B, and meprin α knockout mice on a C57BL/6 background, which are deficient in meprin
A. Cecal ligation and puncture was performed 4 weeks post STZ injection. Blood was collected pre
and post CLP to evaluate blood urea nitrogen (BUN) levels. The mice were sacrificed 18hr post CLP
and kidney tissue processed for proteomic analysis. BUN levels were significantly higher in CLP
mice and meprin α knockout mice had lower mortality rates in comparison to wild-type mice. The
results show that meprin deficiency protected mice from kidney injury associated with CLP,
suggesting that meprins play a role in kidney injury following CLP-induced sepsis.
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CHAPTER 1
Introduction
Diabetes is the most rampant endocrine disease and affects millions of Americans alone.
Diabetic nephropathy (DN) is one of the major microvascular complications of diabetes and it is
associated with a rise in the urinary albumin excretion (UAE) rate and abnormal renal function.
Currently, changes in albuminuria are considered a hallmark of onset or progression of diabetic
nephropathy. Approximately 20–30% of patients with type 1 or type 2 diabetes develop evidence
of nephropathy (Ailing Lu and Anupam Agarwal 2011). Diabetic nephropathy is the leading
cause of end stage renal disease (ESRD). Meprins are metalloproteinases that are highly
expressed in the brush border membranes (BBM) of proximal kidney tubules (Bond & Beynon,
1995; Kounnas et al., 1991). The self-associating homo-oligomeric complexes of meprin A are
secreted as latent proteases (containing the prosequence) and can move through extracellular
spaces in a non-destructive manner, and deliver a concentrated form of this metalloproteinase to
sites that have activating proteases, such as site of inflammation, infection or cancerous growth.
Thus, meprin structures provide means to concentrate proteolytic activity at the cell membrane
(Bond & Beynon, 1995; Kounnas et al., 1991). Meprins have been shown to cleave ECM
proteins such as collagen IV, collagen VI, fibronectin, laminin, and nidogen-1 in vitro (Banerjee
& Bond, 2008; Kaushal et al., 1994; Kohler et al., 2000; Kruse et al., 2004).
Sepsis is a complex medical condition, where the entire body undergoes an inflammatory
state and the presence of a known or suspected infection leads to severe consequences such as
multiple organ failure (Bone et al., 1992). Acute renal failure (ARF) is a common complication
of sepsis and carries an ominous prognosis. Mortality was reported higher in patients with septic
ARF (74.5%) than in those whose renal failure did not result from sepsis (45.2%) (Vriese,
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2003a). Although studies have been conducted, the exact pathogenesis of diabetic nephropathy is
complex and not completely understood. Identifying anomalies of kidney function in the early
stages of diabetic nephropathy is vital to developing an ideal treatment and cure. The objective of
this research was to evaluate the role of meprins in the kidney injury associated with CLPinduced sepsis using a meprin α deficient mouse model.
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CHAPTER 2
Literature Review
2.1 Diabetes
Diabetes is a chronic systemic disease characterized by high levels of glucose in the
blood. Types 1 and 2 diabetes mellitus together affect more than 20 million Americans and rank
as the sixth leading cause of disease-related death in the United States (Abdin et al., 2010; A. Red
Eagle et al., 2005; Wada & Makino, 2013). People with diabetes have high blood glucose levels

due to either the lack of insulin production by the pancreas or the inability of cells to process
insulin. Patients with high blood sugar will typically experience polyuria (frequent urination),
they will become increasingly thirsty (polydipsia) and hungry (polyphagia). In the body, the
metabolic hormone insulin is imperative to blood glucose homeostasis. Insulin is produced by
pancreatic β cells in the body(H.M. Wagner E., Bloom D., and Camerini D, 1998).
The onset of type-1 diabetes is directly linked to the malfunction of these pancreatic β cells in the
body. People usually develop type 1 diabetes before their 40th year, often in early adulthood or
teenage years. Type 1 diabetes requires treatment with insulin or transplantation of pancreatic b
cells. Patients with type 1 diabetes will need to take insulin injections for the rest of their
life(H.M. Wagner E., Bloom D., and Camerini D, 1998). They must also ensure proper bloodglucose levels by carrying out regular blood tests and following a special diet. By contrast, the
majority of the diabetic population has type 2 diabetes, which is not insulin-dependent. In most
cases this form of diabetes does not require insulin therapy. Type 2 diabetes is characterized by
persistent hyperglycemia, impaired glucose tolerance, glomerular hyperﬁltration, and
progression of albuminuria, ultimately leading to renal injury(Schena, 2005).
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The prevalence of diabetes is projected to increase from 171 million in 2000 to 366
million in 2030, as a result of growth, aging, urbanization, and physical inactivity (Wild et al.,
2004). Type-1 and type-2 diabetes continue to increase on an epidemic scale and have become a
major public health concern globally. Identifying new therapeutic targets are critical to
suppressing this epidemic.
2.1.2 Complications of Diabetes Diabetes is associated with several complications.
These include: weight loss, polyuria, hypertension, blurred vision and diabetic nephropathy
(DN).
2.2 Diabetic Nephropathy
Diabetic nephropathy is one of the most severe microvascular complications of diabetes
mellitus and is also a major cause of end-stage renal disease(Schena, 2005). Diabetic
nephropathy is associated with albuminuria, proteinuria and reduction in glomerular ﬁltration
rate (Ching Ye Hong, 1998). The elevated levels of serum creatinine and blood urea nitrogen are
considered to be an index of diabetic nephropathy. In the glomeruli, mesangial cells are
considered to be a primary target for the insult induced by increased glomerular capillary
pressure and play a crucial role in the glomerular trafficking of plasma proteins, their deposition,
and extracellular matrix (ECM) protein accumulation within the mesangium (Luca Paris, 2008).
This leads to the development and progression of glomerular sclerotic lesions in various
glomerular diseases such as diabetic nephropathy. The thickening of basement membranes in
capillaries and small vessels of diabetic patients is considered to be a characteristic
histological finding in diabetic nephropathy (Rafel Sim, 1996).
Ethnic disposition to ESRD varies greatly across different racial groups. In figure 1
shown below, both the rates of incident of ESRD caused by diabetes and their growth over time
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vary widely by age and race/ethnicity (Health, 2013). Among whites age 30–39, for example, the
rate (adjusted for gender) has increased just 3.5 percent since 2000, reaching 37 per million in
2011. For blacks/African Americans of the same age, in contrast, the rate has increased 72
percent since 2000, to reach 136 per million. Different patterns are seen among older populations
in the same figure. The 2011 rate of incident ESRD due to diabetes among whites age 50–59 is
nearly the same as in 2000, while rates have fallen 27 and 50 percent, respectively, among
blacks/African Americans and Native Americans of the same age(Health, 2013). The wide
variation of incidence of ESRD caused by diabetes is not fully understood.

Figure 1. Adjusted incident rates of ESRD due to diabetes, by age, race, & ethnicity.
2.2.1 Histology of Diabetic Nephropathy Diabetic nephropathy development is
characterized by the progressive change in kidney function. This change occurs in series of
stages. During the initial stages, diabetics experience hyperglycemia and glomerular
hyperfiltration(Ayo, 1990). Subsequent stages include thickening of the glomerular basement
membrane, mesangial cell expansion, proteinuria, acute and severe hypertension, and the
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eventual decline in glomerular filtration rate (GFR). These stages ultimately lead to end stage
renal disease (ESRD) (Ching Ye Hong, 1998). It should also be noted that the loss of renal
functionality leads to a decline in nephrons and accumulation of extracellular matrix (ECM).
ECM abundance has been linked to upregulation of transforming growth factor-β (TGF-β), a
fibrogenic cytokine (Eddy & Neilson, 2006; Lan, 2011). Production of TGF-β stimulates ECM
synthesis while inhibiting degradation (Lan, 2011). Treatment with anti-TGF-β in db/db mice, a
mouse model of type-2 diabetes showed decreased glomerular basement membrane thickening
and mesangial matrix accumulation (Chen et al., 2003). Extracellular matrix buildup in the
diabetic kidney surpasses degradation and initiates glomerulosclerosis and tubulointerstitial
fibrosis (Chen et al., 2003).
Hyperglycemia also causes an increase in the synthesis of fibronectin, laminin, and type
IV collagen in glomerular mesangial cells. Laminin, an adhesive glycoprotein, is the main
non-collagenous constituent of the basement membrane and is up regulated in diabetic patients
(Rafel Sim, 1996). In recent years, biochemical and immunohistochemical approaches have
been developed to characterize the changes of laminin in basement membrane and
alterations of the metabolism and distribution of this protein have been described in
diabetic animals and also in humans (Rafel Sim, 1996). Fibronectin is involved in
coagulation, platelet formation, tissue repair, and may reduce erythrocyte deformity and
filterability in diabetic patients (Ching Ye Hong, 1998). Glomerular mesangial cells are
considered to be exposed to the stretch stress due to glomerular hypertension and are found to
produce the excess amount of extracellular matrix (ECM) proteins including fibronectin when
exposed to the mechanical stretch. This is important because increases in mesangial cell
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proliferation and extracellular matrix proteins, such as fibronectin , ultimately result in
thickening of the glomerular basement membrane (Ailing Lu & Anupam Agarwal, 2011).
Understanding the pathogenesis of diabetic nephropathy, along with its complications, in the
early stages is necessary to develop targeted therapies to detect alterations in kidney function. It
remains to be fully defined as to which pathways in diabetic complications are essentially
protective rather than pathological, in terms of their effects on the underlying disease process.
Today, clinical indicators of diabetic nephropathy include blood urea nitrogen (BUN),
proteinuria, serum creatinine, and glomerular filtration rate (GFR) measurements to asses kidney
function(Bluestone, 2010).
2.2.2 Role of Mesangial Cells in Diabetic Nephropathy In the glomeruli, mesangial
cells are considered to be a primary target for the insult induced by increased glomerular
capillary pressure and play a crucial role in the glomerular trafficking of plasma proteins, their
deposition, and extracellular matrix (ECM) protein accumulation within the mesangium (Luca
Paris, 2008). Secretion of ECM proteins by mesangial cells could thus, lead to the development
and progression of glomerular sclerotic lesions in various glomerular diseases such as DN. The
thickening of basement membranes in capillaries and small vessels of diabetic patients is
considered to be a characteristic histological finding in DN (Rafel Sim, 1996).
Fibronectin is involved in coagulation, platelet formation, tissue repair, and may reduce
erythrocyte deformity and filterability in diabetic patients (Ching Ye Hong, 1998). It is believed
that mesangial cell proliferation and extracellular matrix accumulation play crucial roles in early
renal hypertrophy and later glomerular sclerosis in diabetic nephropathy. Mesangial cells excrete
more extracellular proteins under high glucose conditions, but the mechanism behind this is not
understood. Glomerular mesangial cells are considered to be exposed to the stretch stress due to
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glomerular hypertension and are found to produce the excess amount of extracellular matrix
(ECM) proteins including fibronectin and laminin when exposed to the mechanical stretch (Luca
Paris, 2008). This is important because increases in mesangial cell proliferation and extracellular
matrix proteins, including

fibronectin , ultimately result in thickening of the glomerular

basement membrane (Ailing Lu & Anupam Agarwal, 2011). This ultimately leads to impaired
renal function.

Previous studies have demonstrated that high glucose levels stimulated

mesangial cell proliferation and fibronectin expression leading to extracellular matrix deposition.
Laminin, an adhesive glycoprotein, is the main non-collagenous constituent of the
basement membrane and is up regulated in diabetic patients. In recent years, biochemical and
immunohistochemical approaches have been developed to characterize the changes of
laminin in basement membrane and alterations of the metabolism and distribution of this
protein have been described in diabetic animals and also in humans (Rafel Sim, 1996).
The most widely used marker for laminin metabolism in humans is the LPl fragment and
its assay in serum has proved useful in the monitoring of patients with malignancies and
liver disease. These pathways ultimately lead to increased renal albumin permeability and
extracellular matrix accumulation, resulting in increasing proteinuria, glomerulosclerosis and
ultimately tubulointerstitial ﬁbrosis (Luca Paris, 2008).
2.2.3 Signaling Pathways Involved in Extracellular Matrix Metabolism The protein
kinases regulate a series of cellular processes during growth and development. Protein kinases
are an integral part of the machinery that is activated in response to stress, they are essential for
memory, and they are directly involved in orchestrating cell death (S.S. Taylor, 2006). These
enzymes are primary targets for therapeutic intervention. Examining the localization and
signaling between these protein kinases will provide some explanation in the hyper-excretion of
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these extracellular basement proteins which ultimately lead to renal fibrosis and diabetic
nephropathy. Several treatment strategies are available to cure diabetic nephropathy or reduce its
progression. These include modalities used to suppress the renin–angiotensin–aldosterone system
and control blood glucose levels (Eades, 2009). However, diabetic patients are still reaching end
stage renal disease at an alarming rate. Conventional therapeutic strategies are not fully
efficacious in the treatment of diabetic nephropathy, suggesting an incomplete understanding of
the gene regulation mechanisms involved in its pathogenesis (Eades, 2009).
2.2.4 Sepsis and the Immune Response Sepsis is a complex medical condition, where
the entire body undergoes an inflammatory state and the presence of a known or suspected
infection leads to severe consequences such as multiple organ failure (Bone et al., 1992). Sepsis
serves as diabetes most common co-morbidity. Acute renal failure (ARF) is a common
complication of sepsis and carries an ominous prognosis. Mortality was reported higher in
patients with septic ARF (74.5%) than in those whose renal failure did not result from sepsis
(45.2%) (Vriese, 2003b). Inflammatory cells infiltrate the kidney, causing local damage by
release of oxygen radicals, proteases, and further production of inflammatory cytokines.
Cytokines act as polypeptides regulating inflammatory and immune responses through actions on
cells (Hewlett M. Wagner E., Bloom D., and Camerini D, 2004). Inflammatory cytokines,
mainly IL-1, IL-6, and IL-18, as well as TNF-α, are involved in the development and progression
of diabetic nephropathy (Vriese, 2003b). As shown below in figure 2, the three significant steps
in sepsis are vasodilation and vascular leak, leukocyte recruitment, and coagulation and
neutrophil extracellular trap (NET) formation. Local inflammatory mediators, including tumor
necrosis factor (TNF) and interleukin (IL)-1β, lead to vasodilation (Hewlett M. Wagner E.,
Bloom D., and Camerini D, 2004). This recruits leukocytes to sites of infection and sets off a
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cascade of leukocyte activation, NET formation, and coagulation (Vriese, 2003b). The
recognition of these molecules as significant pathogenic mediators in diabetic nephropathy
leaves open the possibility of new potential therapeutic targets (Hewlett M. Wagner E., Bloom
D., and Camerini D, 2004). Those suffering from systemic sepsis suffer from acute lung injury,
acute kidney injury, and even death.

Figure 2. Schematic of Sepsis.

People with diabetes may also be at increased risk of developing acute renal failure
(ARF). The presence of underlying diabetic nephropathy may predispose to ARF resulting from
adverse effects such as hypotension, sepsis or exposure to nephrotoxic agents (Ching Ye Hong,
1998). Understanding the role that the immune system plays in the pathogenesis of diabetic
nephropathy could lead to identification of new strategies and/or additional therapeutic targets
for prevention and treatment of diabetic nephropathy (Hewlett M. Wagner E., Bloom D., and
Camerini D, 2004).

13
2.3 Meprins
Meprins are cell surface and secreted proteases highly expressed in the brush border
membranes of proximal kidney tubules (Bertenshaw et al., 2001; Bond, Matters, Banerjee, &
Dusheck, 2005; Kounnas, Wolz, Gorbea, & Bond, 1991). Meprins are members of the astacin 8
family of metalloproteases (Bond & Beynon, 1995). Meprin A and meprin B are disulfidelinked, tetrameric metalloendopeptidases in renal brush border membranes. Meprins are highly
expressed at the brush border membrane of proximal tubule cells of the kidney and epithelial
cells of the intestine (Carlos M. Gorbea, 1991). Meprin proteases are composed of two
evolutionarily related subunits, α and β, that are approximately 50% identical at the amino acid
level. The subunits are encoded on two genes: the α gene is on human chromosome 6 (mouse 17)
near the histocompatibility complex; the β subunit on chromosome 18 in both the mouse and
human genomes (Judith S. Bond, 2005). The self-associating homo-oligomeric complexes of
meprin A are secreted as latent proteases (containing the prosequence) and can move through
extracellular spaces in a non-destructive manner, and deliver a concentrated form of this
metalloproteinase to sites that have activating proteases, such as site of inflammation, infection
or cancerous growth (Carlos M. Gorbea, 1991). In situ hybridization studies of embryonic and
adult mice and immunohistochemistry demonstrated the tissue-specific expression of meprin
subunits in the epithelial cells of kidney and intestine only. Kidney expressions of mouse meprin
subunits are strain-dependent; all strains express both subunits during fetal stages. Some strains
increase both subunits after birth (e.g., C57BL/6) while others only express meprin β, and down
regulate mepin α (e.g., C3H/He) (Judith S. Bond, 2005). Meprin structures provide means to
concentrate activity at the cell membrane.
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Researchers also determined the tissue-specificity of meprin subunits in embryonic and
adult mice. The study established that the expression of kidney meprin subunits is dependent on
the strain of mice; C57BL/6 mice expresses both α and β meprin subunits whereas adult C3H/He
lack the meprin α subunit (Kumar & Bond, 2001). Within the kidney, meprin expression is
normally restricted to the brush-border membrane, however when injury occurs, meprins are
transferred to other cell compartments. This transfer of meprins to other cellular compartments
can increase damage to kidney tissue.
2.3.1 Meprins Structures Meprins are composed of two subunits, alpha (α) and beta (β),
that are evolutionarily related but differ in function and structure (Bond & Beynon, 1995; Wolz
& Bond, 1995). The α and β subunits are encoded by two distinct genes on chromosomes 6 and
18 in humans and 17 and 18 in mice (Bond, Rojas, Overhauser, Zoghbi, & Jiang, 1995). Meprin
A consists of homo-oligomeric α/α complexes and hetero-oligomeric α/β complexes, while
meprin B is a homo-oligomer of β/β complexes (Beynon, Oliver, & Robertson, 1996; Bond &
Beynon, 1995; Gorbea et al., 1993). Meprin β subunits are integral membrane proteins that
consist of a short cytoplasmic tail and a trans-membrane domain (Johnson & Hersh, 1994;
Marchand, Tang, & Bond, 1994). The meprin subunits form homo or hetero complexes linked by
disulfide bonds and can be expressed separately or coordinately (Bond et al., 2005). When the
subunit α is associated with a β subunit, it remains attached to the cell membrane.
2.3.2 Meprins Substrates Meprins are highly conserved among different species and are
capable of degrading a wide range of proteins, such as ECM proteins collagen IV, collagen VI,
fibronectin, laminin, and nidogen-1 in vitro (Banerjee & Bond, 2008; Kaushal, Walker, & Shah,
1994; Kohler, Kruse, Stocker, & Sterchi, 2000; Kruse et al., 2004). Both α and β subunits have
specific substrates that are capable of being degraded such as bradykinin (Bertenshaw, Villa,
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Hengst, & Bond, 2002) for meprin A and gastrin (Bertenshaw et al., 2001) , orcokinin
(Bertenshaw et al., 2002), pro-inflammatory cytokines (Marchand et al., 1994; Norman, Matters,
Crisman, & Bond, 2003), E-cadherin (Huguenin et al., 2008) and protein kinases (Chestukhin,
Litovchick, Muradov, Batkin, & Shaltiel, 1997) for meprin B. Meprins also cleave parathyroid
hormone (Yamaguchi, Fukase, Sugimoto, Kido, & Chihara, 1994), biologically active peptides
(Kohler et al., 2000; Sterchi, Naim, Lentze, Hauri, & Fransen, 1988) and chemokines. The
localization of meprins at the interface with the external environment, at leukocytes at
inflammatory sites, and in response to bacterial infections implicates them in host defense.
2.3.3 Meprins and Diabetic Nephropathy Meprins have been linked with a variety of
pathological conditions such as ischemia-reperfusion, induced acute renal failure, diabetic
nephropathy, and fibrosis. Other studies demonstrate that low levels of meprin A are associated
with the development of chronic nephropathy and fibrosis in animal models of diabetes (Bond et
al., 2005; Mathew et al., 2005). Researchers used polymerase chain reaction to determine
variations in the meprin β gene in Pima Indians, a Native American tribe with significantly high
rates of type 2 diabetes and diabetic nephropathy (A. R. Red Eagle et al., 2005). This critical
study revealed 19 single nucleotide polymorphisms (SNPs) in the meprin β gene, suggesting that
there are genes that make individuals susceptible to diabetic nephropathy (A. R. Red Eagle et al.,
2005). Urine samples were collected from premenopausal women with histories of urinary tract
infections (Bond et al., 2005). Researchers found that women with acute urinary tract infections
had high or very high levels of meprin in the urine (Bond et al., 2005).
2.3.4 Meprins and Cecal Ligation and Puncture Induced Sepsis Sepsis is a disorder
initiated by excessive activation of innate immunity. It is a serious medical problem particularly
in patients in the intensive care unit (ICU) where it is the second leading cause of death in non-
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coronary ICU patients. Acute renal injury (AKI) occurs in 20%–50% of septic patients and
nearly doubles the mortality rate of sepsis (A. R. Red Eagle et al., 2005). There is a growing
recognition of the need for treatment regimens that target both the early systemic and later
kidney-specific effects of sepsis in patients. Meprins are also capable of proteolytically
processing cytokines and chemokines (Hewlett M. Wagner E., Bloom D., and Camerini D,
2004). For example, meprin A and meprin α are capable of generating biologically active IL-1β
from its precursor pro-IL-1β (Herzog C, 2009). Recent studies have demonstrated that meprin-α
knockout mice were protected against lipopolysaccharide (LPS)-induced AKI. This finding
supported a recent study shown that actinonin administered at the time of induction of sepsis by
cecal ligation and puncture (CLP) in mice reduced renal injury (Holly MK, 2006). However, this
study did not address the mechanism of protection. Since current therapy is mostly supportive
and largely ineffective there is a critical need to uncover new therapeutic approaches because the
incidence of sepsis-induced AKI is predicted to increase as the population ages (Jandeleit-Dahm,
2006).
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CHAPTER 3
Methodology
3.1 Reagents
The following chemicals were purchased from Sigma-Aldrich (St Louis, MO): mannitol,
sodium citrate, sodium chloride, sodium dodecyl sulfate, streptozotocin (STZ)
tetramethylethylenediamine (TEMED) and triton X-100. The following chemicals were
purchased from Fisher Scientific (Pittsburgh, PA): β-mercaptoethanol, acetic acid, ammonium
persulfate, choloroform, ethylenediaminetetraacetic acid (EDTA), EZ-Run pre-stained rec
protein ladder, fat-free milk, 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES),
isobutyl alcohol, hydrochloric acid, magnesium chloride, methanol, sodium orthovanadate, tris
base, and tween 20. The following chemicals were purchased from Bio-Rad (Hercules, CA):
anti-mouse IgG secondary antibody, anti-rabbit secondary antibody, Bio-Rad’s protein reagent,
30% acrylamide (29:1 bis solution). Dr Judith Bond from Pennsylvania State University College
of Medicine (Hershey, PA) donated anti-meprin-A polyclonal rabbit and anti-meprin-B
polyclonal rabbit antibodies. Anti-PKA mouse monoclonal antibody was purchased from BD
Biosciences (Greensboro, NC). The following chemicals were purchased from Thermo Scientific
(Waltham, MA): ethyl alcohol 200 proof (Acros Organics), 100X EDTA solution, 100X halt
protease inhibitor cocktail and West Pico ® chemiluminescent substrate.
3.2 Experimental Animals
Wild-type male mice on a C57BL/6 background were purchased from Charles River
Laboratories (Wilmington, MA). Meprin α knockout (αKO) mice on a C57BL/6 background
were bred in Laboratory Animal resource Unit (LARU) at North Carolina Agricultural &
Technical State University. All mice were housed in standard cages with 5 mice per cage with a
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12:12 hour light:dark cycles and were fed a standard mouse chow (Purina Laboratory Chow
5001; Purina Mills, St Louis, MO) and water ad libitum. All animal protocols were approved by
the North Carolina A&T State University Institutional Animal Care and Use Committee
(IACUC).
3.3 Induction of Diabetes in Mice
Low dose streptozotocin (STZ) was used to induce type-1 diabetes in 8 week old mice.
STZ was dissolved in sodium citrate buffer (10 mmol/L, pH 4.5) to make a stock of 7.5 mg/mL.
STZ was used within 15 minutes of preparing and kept from light to avoid degradation. Mice
were injected with STZ at 55 mg/kg using a 29G insulin needle, to induce type-1 diabetes.
Control mice were injected with equivalent volumes of sodium citrate buffer. Injections were
repeated for 5 consecutive days. All mice were fasted for 6 hours prior to injections. Mice were
weighed prior to injections and every week thereafter. Blood glucose levels were measured for
each mouse at 10 days post-STZ injections using a Reli-On® Blood Glucose Monitoring System
(ARKRAY USA, Minneapolis, MN). STZ-injected mice with a blood glucose level ˃250 mg/dL
were considered diabetic.
3.4 Cecal Ligation and Puncture
Mice were anesthetized with Ketamine (100 mg/kg) and Xylazine (100 mg/kg) dissolved
in 0.9 % sterile saline solution intraperitoneal. The lower abdominal quadrant of each mouse was
shaved using an electric trimmer and disinfected with Betadine and Nolvasane 3x. Applied eye
ointment to the eyes and monitored the intensity of anesthesia by a toe pinch. A midline
longitudinal incision was made to exteriorize the cecum and contents within the cecum were
pushed toward the blind end ~15cm from end. The ligated cecum was perforated by a single
through-and-through puncture with a 21-gauge needle and squeezed to extrude a 1 mm column
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of fecal material. In sham-operated mice, the cecum was located, but neither ligated nor
punctured. The cecum was relocated into the abdominal cavity. The abdominal incision was
closed in two layers with 5-0 nylon sutures running sutures. After surgery, 1 ml of pre-warmed
0.9% sterile saline solution was injected intraperitoneally. Mice were allowed to recover then
returned to cages with food and water on pre-warmed deltaphase isothermal pads. Six hours
post-CLP mice were given Buprenorphrine (0.3 mg/ml) dissolved in 0.9 % sterile saline solution
intraperitoneal for pain.
3.5 Tissue Collection and Analysis
Blood and urine samples were collected at 4 weeks post-STZ injections. Blood samples
were collected from each C57BL/6 mouse by nicking the tail vein and drawing into
lithium/heparin tubes (Sarstedt, Newton, NC), which prevent clotting of the blood. Blood was
collected at 4 weeks post-STZ injections for both male and female mice. Blood samples were
centrifuged at 10000 x g for 10 minutes at 4˚ C. Plasma was stored at -80 ˚C until used for
kidney assessments. Spot urine samples were collected by bladder massage. To harvest kidney
tissue, the mice were put to death by inhalation of CO2. Both left and right kidneys were
removed and decapsulated. Half of the kidney was wrapped in aluminum foil, snap-frozen in
liquid nitrogen and stored at -80 ˚C for proteomic analysis. Other sections of each kidney were
cut and placed into Carnoy’s fixative (60% Methanol, 30% Chloroform, 10% Acetic Acid)
overnight. The kidney sections were then removed from the fixative and stored in 70% Ethanol
at 4˚C. Kidney tissue was embedded in paraffin embedded and 5 μm cross sections were cut onto
Superfrost plus microscope slides (Fisher Scientific, Pittsburgh, PA) for histology.
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3.6 Blood Urea Nitrogen Assay
To evaluate kidney function, blood urea nitrogen (BUN) was measured at 4 weeks postSTZ injections using the stored plasma samples. BUN was assessed using BUN chemistry slides
(Ortho Clinical Diagnostics, Rochester, NY) and then analyzed on the Vitros DT6011 Analyzer
(Ortho Clinical Diagnostics, Rochester, NY).
3.7 Fractionation of Kidney Proteins
Mice kidneys, previously stored at -80 ˚C were thawed and fractionated into cytosolic-,
brush border membrane- and structural-enriched fractions. Additionally, samples containing total
protein content were obtained. Kidneys were homogenized in 9 volumes of Kidney Brush Border
Homogenization Buffer (2mM Tris HCl, pH 7.0 with 10 mM Mannitol). A 1 M stock of MgCl2
was added for a final concentration of 10 mM and stirred at 4 ˚C for 14 minutes. The
homogenate was centrifuged at 15000 x g at 4 ˚C for 15 minutes and the supernatant was
transferred to a new microcentrifuge tube. The supernatant was centrifuged at 15000 x g at 4˚C
for 15 minutes; afterward the supernatant was transferred into a new microcentrifuge tube and
stored at -80 ˚C as the cytosolic-enriched fraction. The pellet was resuspended in 500 μL Kidney
Brush Border Homogenization Buffer and centrifuged at 2200 x g at 4 ˚C for 15 minutes. The
supernatant was centrifuged at 2200 x g for 15 minutes and discarded. The pellet was
resuspended in 100 μL Kidney Brush Border Homogenization Buffer and stored at -80 ˚C as the
brush border membrane-enriched fraction. Radioimmunoprecipitation Assay buffer (RIPA) (0.02
mM HEPES pH 7.9, 0.015 mM NaCl, 0.1 mM Triton-X 100, 0.01 mM SDS, 1 mM Na3VO4)
with 10% 0.5 M EDTA was used to extract total protein mix and kept on ice for 30 minutes. The
homogenate was centrifuged at 16100 x g at 4 ˚C for 10 minutes and supernatant was transferred
into a new microcentrifuge tube then stored at -80 ˚C. Supernatant is the total-enriched fraction.
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Proteins concentrations from all fractions were determined by the Bradford Reagent Protein
Assay Method, using Bio-Rad’s Protein Assay Reagent (Hercules, CA).
3.8 Western Blot Analysis
Western blot analysis was used to quantify the kidney protein levels of meprin A, meprin
B and the catalytic subunit of protein kinase A (PKAcat). Equal amounts of kidney protein (3080 μg) were loaded into 10% prepared Sodium Dodecyl Sulfate Polyacrylamide Gels (SDSPAGE) and allowed to separate by electrophoresis for 1 hour at 200 Volts. Proteins from the gels
were transferred to nitrocellulose membrane (Bio-Rad, Richmond, CA) using a Trans-Blot SD
Semi-Dry Transfer Cell Unit (Bio-Rad, Richmond, CA). To block nonspecific binding sites,
membranes were incubated in 8% fatty-free milk in Tris-buffered saline with 0.1% Tween 20
(TBS-T) for 1 hour at room temperature with gentle shaking. Nitrocellulose membranes were
incubated with primary antibodies overnight at 4˚C or at room temperature for 1 hour. The
primary antibodies used were polyclonal rabbit anti-meprin α and β (Hershey Medical Center,
Hershey, PA), diluted 1:5000 and mouse monoclonal anti-PKAcat (BD Biosciences Greensboro,
NC), diluted 1:3300. The nitrocellulose membranes were washed three times for 10 minutes at
room temperature. The secondary antibody mouse IgG (Bio-Rad, Hercules, CA) or rabbit IgG
(Bio-Rad, Hercules, CA) was added to the nitrocellulose membranes using a dilution of 1:10,000
overnight at 4˚C or at room temperature for 1 hour. The nitrocellulose membranes were washed
three times for 15 minutes at room temperature. Nitrocellulose membranes were then exposed to
Chemiluminescent Substrates (Thermo Scientific, Waltham, MA) and developed on X-Ray film.
Protein bands were evaluated by densitometry using QuantityOne Software (Bio-Rad, Hercules,
CA).
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3.9 Statistical Analysis
The data were analyzed by two-way ANOVA, with Bonferroni post-test pair-wise
comparisons using Graph Pad Prism Software (GraphPad Software, La Jolla, CA). P values ≤ 0.5
were considered statistically significant.
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CHAPTER 4
Results
4.1 Blood Glucose
Diabetes was confirmed by measuring blood glucose ten days post-STZ injections for
each mouse. Mice with a blood glucose reading > 250 mg/dL are considered diabetic. Blood
glucose levels for STZ-injected WT and meprin αKO mice were significantly higher in
comparison to sodium citrate (NaC) buffer injected mice. Wild-type and meprin αKO mice
subjected to CLP surgery had higher glucose levels than sham operated controls.
***
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Figure 3. WT and αKO 10 Day Glucose Measurements (**= P<0.01;***=P<0.001)
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4.2 WT Pre- vs. Post-Diabetic Body Weights
Body weights were collected at 0 and 4 weeks post STZ injection in WT mice examine
the effects of diabetes on body weight.
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Figure 4. WT body weights 0 weeks diabetic vs. 4 Weeks diabetic. (ns= P<0.05;***=P<0.001) .
4.3 WT BUN Levels Pre- vs. Post-CLP
Plasma samples were processed 0 and 18 hours post CLP to assay BUN in C57BL/6 (WT)
mice. BUN levels were higher in the WT mice 18 hours post CLP surgery.
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Figure 5. WT BUN levels 0 hour and 18 hour CLP (ns= P<0.05;***=P<0.001)
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4.4 αKO BUN Pre- vs. Post-CLP
Plasma samples were processed 0 and 18 hours post CLP to assay BUN in αKO mice. BUN

BUN(Mg/dL)

levels were higher in the αKO mice 18 hours post-CLP surgery.
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Figure 6. αKO BUN levels 0 hour and 18 hour CLP (ns=P<0.05;**=P<0.01)
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Figure 7. WT BUN levels non-diabetic vs. diabetic (ns= P<0.05;***=P<0.001).
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Figure 8. Serum creatinine levels in WT mice pre and post CLP.
4.7 CLP Mortality Rates
Mortality rates were evaluated for both the sham and CLP induced sepsis mice. 30% of
mice that had undergone CLP induced sepsis died overnight in comparison to 10% of the sham
mice.
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Figure 9. CLP was associated with a high mortality rate.
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4.8 Genotype CLP Mortality Rates
Mortality rates were determined by genotype. 20% of the C57BL/6 (WT) mice died 18
hours post CLP surgery in comparison to 10% of αKO mice.
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Figure 10. Meprin A deficiency decreased CLP-associated mortality
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CHAPTER 5
Discussion and Future Research
Diabetic nephropathy is the leading cause of ESRD worldwide (Ibrahim & Hostetter,
1997, Molitch et al., 2003; A. R. Red Eagle et al., 2005; Thrailkill et al., 2009). It has become an
increasing concern in medicine because it is associated with high mortality and morbidity rates.
Pathological changes observed in diabetic nephropathy include: accumulation of ECM proteins,
proteinuria, renal hypertrophy, glomerular basement membrane thickening, mesangial expansion
and renal fibrosis (Lan, 2011; Maxwell, 2005; Wada & Makino, 2013). Meprin metalloproteases
are abundantly expressed in the BBM of the kidney and have been shown to degrade ECM
proteins. Sepsis is a disorder initiated by excessive activation of innate immunity. It is a serious
medical problem particularly in patients in the intensive care unit (ICU) where it is the second
leading cause of death in non-coronary ICU patients. There is a growing recognition of the need
for treatment regimens that target both the early systemic and later kidney-specific effects of
sepsis in patients. Meprins are also capable of proteolytically processing cytokines and
chemokine. For example, meprin A and meprin α are capable of generating biologically active
IL-1β from its precursor pro-IL-1β (Herzog C, 2009). Recent studies have demonstrated that
meprin-α knockout mice were protected against lipopolysaccharide (LPS)-induced AKI (Hewlett
M. Wagner E., Bloom D., and Camerini D, 2004).
Data from this study suggests that meprin deficient mice that had undergone CLP
induced sepsis had less severe kidney damage than WT mice in comparison to their sham
counterparts. Both WT and αKO mice had higher BUN levels post CLP surgeries. STZ-injected
WT mice had higher BUN levels post CLP in comparison to the control group.
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The mechanisms by which meprins protect against sepsis in diabetic nephropathy are not
fully understood. A potential pathway is through modulation of ECM metabolism. Further
studies need to be done with meprin knockout mice to further evaluate mechanisms by which
meprins protect mice from diabetic kidney damage in septic conditions. Having a suitable model
for DN is critical in advancing research in DN and ultimately identifying biomarkers that can be
used for early diagnosis of patients at risk for DN. Early diagnosis is important in providing
targeted treatments to patients and decreasing both mortality and morbidity rates.
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